CA2296224A1 - Utilisation d'imidazo(1,5-a)pyrido(3,2-e)pyrazinones - Google Patents

Utilisation d'imidazo(1,5-a)pyrido(3,2-e)pyrazinones Download PDF

Info

Publication number
CA2296224A1
CA2296224A1 CA002296224A CA2296224A CA2296224A1 CA 2296224 A1 CA2296224 A1 CA 2296224A1 CA 002296224 A CA002296224 A CA 002296224A CA 2296224 A CA2296224 A CA 2296224A CA 2296224 A1 CA2296224 A1 CA 2296224A1
Authority
CA
Canada
Prior art keywords
formula
compounds
alkyl
pyrido
14aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002296224A
Other languages
English (en)
Inventor
Norbert Hofgen
Stefan Szelenyi
Degenhard Marx
Ute Egerland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AWD Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/de
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/de
Application filed by Individual filed Critical Individual
Publication of CA2296224A1 publication Critical patent/CA2296224A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002296224A 1999-01-20 2000-01-19 Utilisation d'imidazo(1,5-a)pyrido(3,2-e)pyrazinones Abandoned CA2296224A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19902082.5 1999-01-20
DE1999102082 DE19902082A1 (de) 1999-01-20 1999-01-20 Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
DE1999161302 DE19961302A1 (de) 1999-12-18 1999-12-18 Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
DE19961302.8 1999-12-18

Publications (1)

Publication Number Publication Date
CA2296224A1 true CA2296224A1 (fr) 2000-07-20

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002296224A Abandoned CA2296224A1 (fr) 1999-01-20 2000-01-19 Utilisation d'imidazo(1,5-a)pyrido(3,2-e)pyrazinones

Country Status (23)

Country Link
EP (1) EP1144410A2 (fr)
JP (1) JP2002535330A (fr)
KR (1) KR20010101603A (fr)
CN (1) CN1344268A (fr)
AR (1) AR022318A1 (fr)
AU (1) AU2291200A (fr)
BG (1) BG105714A (fr)
BR (1) BR0007613A (fr)
CA (1) CA2296224A1 (fr)
CO (1) CO5190700A1 (fr)
CZ (1) CZ20012627A3 (fr)
EA (1) EA200100792A1 (fr)
EE (1) EE200100377A (fr)
HU (1) HUP0105132A3 (fr)
ID (1) ID29790A (fr)
IL (1) IL144156A0 (fr)
IS (1) IS5987A (fr)
LT (1) LT2001078A (fr)
LV (1) LV12793B (fr)
NO (1) NO20013334D0 (fr)
SK (1) SK10322001A3 (fr)
TR (1) TR200102121T2 (fr)
WO (1) WO2000043392A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299080B2 (en) 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
WO2016022836A1 (fr) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Composés organiques
WO2016022825A1 (fr) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Composés organiques
US9278097B2 (en) 2003-06-06 2016-03-08 Universitatsklinikum Freiburg Prophylaxis and/or treatment of portal hypertension
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
US9643970B2 (en) 2011-10-10 2017-05-09 H. Lundbeck A/S Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors
US10513524B2 (en) 2015-07-07 2019-12-24 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2470210A1 (fr) * 2001-12-17 2003-06-26 Altana Pharma Ag Nouvelle utilisation d'inhibiteurs de pde5
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
FR2835741B1 (fr) * 2002-02-12 2006-05-05 Oreal Nouveaux coupleurs 6-alcoxy-2,3-diaminopyridine utiles pour la teinture des fibres keratiniques
CN101106997A (zh) 2004-08-17 2008-01-16 约翰·霍普金斯大学 Pde5抑制剂组合物及治疗心脏病征候的方法
WO2009070584A1 (fr) 2007-11-30 2009-06-04 Wyeth Imidazo[1,5-a]pyrazines fusionnées avec aryle et hétéroaryle en tant qu'inhibiteurs de phosphodiestérase 10
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
JP5842640B2 (ja) * 2012-01-31 2016-01-13 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278097B2 (en) 2003-06-06 2016-03-08 Universitatsklinikum Freiburg Prophylaxis and/or treatment of portal hypertension
US8829000B2 (en) 2006-12-13 2014-09-09 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A]quinoxalines as phosphodiesterase 9 inhibitors
US9040536B2 (en) 2006-12-13 2015-05-26 Aska Pharmaceutical Co., Ltd. Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors
US8299080B2 (en) 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
US9643970B2 (en) 2011-10-10 2017-05-09 H. Lundbeck A/S Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors
US9993477B2 (en) 2011-10-10 2018-06-12 H. Lundbeck A/S Substituted imidazo[1,5-a]pyrazines as PDE9 inhibitors
US9850249B2 (en) 2012-01-26 2017-12-26 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
US9533992B2 (en) 2012-01-26 2017-01-03 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
WO2016022825A1 (fr) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Composés organiques
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2016022836A1 (fr) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Composés organiques
US10005789B2 (en) 2014-08-07 2018-06-26 Intra-Cellular Therapies, Inc. Organic compounds
US10513524B2 (en) 2015-07-07 2019-12-24 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US11608342B2 (en) 2015-07-07 2023-03-21 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases

Also Published As

Publication number Publication date
NO20013334L (no) 2001-07-05
EP1144410A2 (fr) 2001-10-17
EA200100792A1 (ru) 2002-10-31
BR0007613A (pt) 2001-10-30
LV12793A (lv) 2002-02-20
WO2000043392A3 (fr) 2000-09-28
HUP0105132A3 (en) 2002-12-28
LV12793B (lv) 2002-05-20
JP2002535330A (ja) 2002-10-22
LT2001078A (en) 2002-08-26
IS5987A (is) 2001-06-29
EE200100377A (et) 2002-10-15
WO2000043392A2 (fr) 2000-07-27
NO20013334D0 (no) 2001-07-05
CN1344268A (zh) 2002-04-10
AU2291200A (en) 2000-08-07
IL144156A0 (en) 2002-05-23
AR022318A1 (es) 2002-09-04
TR200102121T2 (tr) 2002-01-21
CZ20012627A3 (cs) 2002-01-16
BG105714A (en) 2002-02-28
CO5190700A1 (es) 2002-08-29
HUP0105132A2 (hu) 2002-05-29
ID29790A (id) 2001-10-11
KR20010101603A (ko) 2001-11-14
SK10322001A3 (sk) 2002-07-02

Similar Documents

Publication Publication Date Title
CA2296224A1 (fr) Utilisation d'imidazo(1,5-a)pyrido(3,2-e)pyrazinones
EP1461039B1 (fr) Compositions pharmaceutiques comportant cilostazol et un inhibiteur d'apport d'adenosine
JP2004500425A (ja) パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
SK13232002A3 (sk) Použitie pyrido[3,2-e]-pyrazinónov ako inhibítorov fosfodiesterázy 5 na liečbu erektilnej dysfunkcie
RO119225B1 (ro) Derivaţi de adenozină, procedeu de preparare şi compoziţie farmaceutică
EP2327408A1 (fr) Inhibiteurs de la phosphodiesterase gmp-spécifique cyclique tetracyclique pour le traitement de l'hyperplasie prostatique bénigne
JPH09132528A (ja) コルチコトロピン放出因子アンタゴニストの新規使用
TWI388556B (zh) 醫療組合物
JP2002529467A (ja) 勃起不全治療に効果を持つピラゾロピリミジノン化合物
WO1998008516A1 (fr) Preparations servant a la prevention et au traitement de maladies provoquees par une hypofonction de l'oxyde nitrique synthase
US20020147174A1 (en) Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
JPH05155887A (ja) アゾール誘導体
CN101014344A (zh) 可用于治疗外周动脉疾病并且作为磷酸二酯酶抑制剂的喹唑啉衍生物
JP4217605B2 (ja) ピラジノ［１’，２’：１，６］ピリド［３，４−ｂ］インドール−１，４−ジオン誘導体
US6992192B2 (en) Carboline derivatives as PDE5 inhibitors
US6465465B1 (en) Process for the treatment of erectile dysfunction and product therefor
JP4339679B2 (ja) Ｐｄｅ５阻害剤としてのカルボリン誘導体
JP2002522388A (ja) 性機能障害の治療のためのピリジノン
JP2004513128A (ja) Ｐｄｅ５阻害剤としてのインドール誘導体
MXPA01007380A (en) Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments
ZA200105719B (en) Use of imidazo[1,5-A]-pyrido[3,2-E]-pyrazinones as medicaments.
JPH07110860B2 (ja) １−（イミダゾ〔１，２−ａ〕ピリジン−６−イル）−２−プロパノン誘導体
DE19961302A1 (de) Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
JP4582561B2 (ja) 移植による血管病変の発生抑制剤
KR20020095469A (ko) 발기부전을 치료하기 위한, 피리도[3,2-ｅ]-피라지논의포스포디에스테라제 5의 억제제로서의 용도

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20040119